Pharmaceuticals

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025–2029: Competitive Insights and Opportunities

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry In 2025?

The poly (adp-ribose) polymerase (parp) inhibitors market has experienced substantial expansion in recent years. It is projected to expand from $5.58 billion in 2024 to $6.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.9%. This historical growth can be linked to factors such as rising healthcare spending, an increasing need for maintenance treatments, the growing application of combination therapies, the emerging focus on personalized medicine approaches, and greater investment in oncology pipelines.

The market for poly (adp-ribose) polymerase (parp) inhibitors is projected to experience substantial expansion in the coming years. By 2029, its valuation is anticipated to reach $11.05 billion, demonstrating a compound annual growth rate (CAGR) of 14.6%. This anticipated growth during the forecast period stems from factors such as the rising incidence of cancer, the wider acceptance of targeted therapies, an expanding elderly demographic, heightened awareness surrounding genetic testing, and increased engagement in clinical trials. Key trends characterizing this period encompass breakthroughs in genomic sequencing technologies, the creation of companion diagnostic instruments, the incorporation of technology into drug development platforms, and the progression of next-generation poly (ADP-ribose) polymerase (PARP) inhibitors.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24662&type=smp

What Are The Top Growth Drivers Impacting The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Outlook?

An increasing incidence of breast cancer is anticipated to drive the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market in the future. Breast cancer is a condition where abnormal cells within the breast multiply uncontrollably, potentially forming a tumor and spreading to other body parts. The growing number of breast cancer cases is attributed to lifestyle factors such as obesity, inactivity, and alcohol consumption, which raise estrogen levels and promote tumor development. Poly(ADP-ribose) polymerase (PARP) inhibitors assist breast cancer treatment by specifically targeting cancer cells with DNA repair deficiencies, particularly BRCA mutations. They reduce tumor proliferation by preventing DNA repair, offering a targeted therapy that enhances patient outcomes and lessens damage to healthy cells. For instance, in March 2025, according to Breastcancer.org, a US-based nonprofit organization, breast cancer makes up about 32% of all new cancer diagnoses, with an estimated 316,950 women projected to be diagnosed with invasive breast cancer, including 59,080 cases of non-invasive types, by 2025. Therefore, the rising number of breast cancer cases is fueling the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market.

What Are The Different Segment Classifications Within The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

The poly (ADP-ribose) polymerase (PARP) inhibitors market covered in this report is segmented –

1) By Drug Type: Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Other Drug Types

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Other Applications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users

Which Competitive Trends Are Defining The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Structure?

Key companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are concentrating on developing innovative solutions, such as combination therapies, to improve drug effectiveness, lessen side effects, and expand treatment applications beyond oncology. Combination therapies are treatment approaches that utilize two or more therapeutic agents, including drugs, radiation, or biologics, simultaneously to boost overall efficacy and enhance patient outcomes. For example, in June 2023, Merck & Co. Inc., a US-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, gained approval from the U.S. Food and Drug Administration (FDA) for olaparib (Lynparza) in conjunction with abiraterone and prednisone (or prednisolone) for adult patients suffering from breast cancer gene (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC). Olaparib (Lynparza) operates by inhibiting PARP enzymes, which prevents DNA repair in BRCA-mutated cancer cells, leading to cell demise. When combined with abiraterone and prednisone (or prednisolone), it amplifies anti-tumor activity by obstructing androgen production, a critical factor for prostate cancer growth, thereby decelerating disease progression.

Which Key Players Are Driving Competition In The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?

Major companies operating in the poly (ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Genentech Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., BeiGene, EMD Serono, Myriad Genetics, Clovis Oncology Inc., Repare Therapeutics Inc., Karyopharm Therapeutics, Checkpoint Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitors-global-market-report

How Do Regional Market Performances Compare Within The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry?

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly (ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24662&type=smp

Browse Through More Reports Similar to the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market 2025, By The Business Research Company

Proton Pump Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Mtor Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795